$220 Million is the total value of Abingworth LLP's 16 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 29.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SIEN | Sientra | $55,151,000 | +31.2% | 2,199,012 | 0.0% | 25.03% | +40.0% | |
| PRTO | Proteon | $36,039,000 | +59.0% | 2,017,872 | 0.0% | 16.36% | +69.7% | |
| PRTK | Paratek | $33,524,000 | -16.3% | 1,301,413 | 0.0% | 15.22% | -10.7% | |
| AMRN | Amarinspons adr | $19,814,000 | +4.7% | 8,087,486 | 0.0% | 8.99% | +11.7% | |
| EVAR | Lombard Medical | $15,110,000 | +14.5% | 3,473,452 | 0.0% | 6.86% | +22.2% | |
| CEMP | Sell | Cempra | $14,738,000 | -18.1% | 428,935 | -18.2% | 6.69% | -12.6% |
| DRNA | Sell | Dicerna | $13,184,000 | -43.5% | 945,757 | -2.8% | 5.98% | -39.8% |
| TBRA | New | Tobira | $10,159,000 | – | 589,244 | +100.0% | 4.61% | – |
| INNL | New | Innocoll | $7,950,000 | – | 555,555 | +100.0% | 3.61% | – |
| ZGNX | Sell | Zogenix | $3,923,000 | +22.6% | 291,902 | -87.5% | 1.78% | +30.9% |
| ANTH | Anthera | $3,767,000 | +92.4% | 437,994 | 0.0% | 1.71% | +105.3% | |
| RGLS | Regulus | $3,588,000 | -35.3% | 327,350 | 0.0% | 1.63% | -30.9% | |
| CCXI | Buy | Chemocentryx | $1,769,000 | +114.7% | 215,000 | +96.0% | 0.80% | +129.4% |
| OGXI | Oncogenex Pharma | $1,407,000 | +10.4% | 603,740 | 0.0% | 0.64% | +17.9% | |
| FLKS | Flex Pharma | $172,000 | -14.0% | 10,000 | 0.0% | 0.08% | -8.2% | |
| ZLCS | Epirus Biopharma | $45,000 | -35.7% | 7,896 | 0.0% | 0.02% | -33.3% | |
| HPTX | Exit | Hyperion | $0 | – | -62,500 | -100.0% | -1.22% | – |
| PTLA | Exit | Portola | $0 | – | -347,349 | -100.0% | -5.61% | – |
| SUPN | Exit | Supernus | $0 | – | -2,303,462 | -100.0% | -11.83% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Abingworth Management LTD #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIENTRA INC | 33 | Q4 2022 | 31.2% |
| PARATEK PHARMACEUTICALS INC | 33 | Q4 2022 | 24.9% |
| CYMABAY THERAPEUTICS INC | 30 | Q4 2022 | 8.6% |
| Ocugen | 24 | Q2 2022 | 1.5% |
| Proteon | 22 | Q3 2020 | 18.9% |
| OBSEVA SA | 22 | Q4 2022 | 5.1% |
| Chiasma | 19 | Q1 2020 | 24.6% |
| VERONA PHARMA PLC | 18 | Q4 2022 | 20.9% |
| Sierra Oncology | 18 | Q2 2022 | 23.1% |
| Crispr | 16 | Q3 2020 | 53.6% |
View Abingworth LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Verona Pharma plc | August 11, 2022 | 21,313,822 | 4.4% |
| Sierra Oncology, Inc.Sold out | July 11, 2022 | 0 | 0.0% |
| HilleVax, Inc. | May 13, 2022 | 1,838,486 | 5.5% |
| SOLENO THERAPEUTICS INC | April 08, 2022 | 18,368,373 | 15.3% |
| Vera Therapeutics, Inc. | April 07, 2022 | 2,970,156 | 11.1% |
| EXICURE, INC. | February 25, 2022 | 7,084,297 | 6.5% |
| Vaxcyte, Inc. | February 14, 2022 | 4,183,716 | 7.9% |
| Jasper Therapeutics, Inc. | October 04, 2021 | 5,628,558 | 15.4% |
| eFFECTOR Therapeutics, Inc. | September 03, 2021 | 4,822,114 | 11.9% |
| Reneo Pharmaceuticals, Inc. | April 20, 2021 | 1,858,226 | 7.7% |
View Abingworth LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-05-03 |
| 4 | 2024-02-12 |
| 13F-NT | 2024-02-02 |
| 13F-NT | 2023-11-03 |
| 4 | 2023-10-02 |
| 13F-NT | 2023-08-04 |
| 4 | 2023-05-10 |
| 13F-NT | 2023-05-05 |
| 13F-HR | 2023-02-10 |
| 4 | 2023-01-31 |
View Abingworth LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.